

Elisa M Ledet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7769858/publications.pdf>

Version: 2024-02-01

33
papers

1,088
citations

686830

13
h-index

476904

29
g-index

33
all docs

33
docs citations

33
times ranked

1911
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines. <i>JAMA Oncology</i> , 2019, 5, 523.	3.4	240
2	The association between germline <i>BRCA2</i> variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. <i>Cancer</i> , 2017, 123, 3532-3539.	2.0	217
3	Individualized Physical 3-dimensional Kidney Tumor Models Constructed From 3-dimensional Printers Result in Improved Trainee Anatomic Understanding. <i>Urology</i> , 2015, 85, 1257-1262.	0.5	79
4	Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents. <i>Oncotarget</i> , 2015, 6, 23358-23371.	0.8	79
5	Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA. , 2020, 8, e001065.		70
6	Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. <i>JAMA Network Open</i> , 2020, 3, e2021692.	2.8	70
7	A Whole Blood Assay for AR-V7 and AR ^{v567es} in Patients with Prostate Cancer. <i>Journal of Urology</i> , 2016, 196, 1758-1763.	0.2	46
8	Inherited TP53 Variants and Risk of Prostate Cancer. <i>European Urology</i> , 2022, 81, 243-250.	0.9	40
9	Circular RNAs add diversity to androgen receptor isoform repertoire in castration-resistant prostate cancer. <i>Oncogene</i> , 2019, 38, 7060-7072.	2.6	31
10	Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. <i>Prostate</i> , 2021, 81, 433-439.	1.2	29
11	Exceptional Duration of Radium-223 in Prostate Cancer With a BRCA2 Mutation. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e69-e71.	0.9	28
12	Clinical Use of PCA3 and TMPRSS2:ERG Urinary Biomarkers in African-American Men Undergoing Prostate Biopsy. <i>Journal of Urology</i> , 2016, 196, 1053-1060.	0.2	19
13	Biomarkers for Programmed Death-1 Inhibition in Prostate Cancer. <i>Oncologist</i> , 2019, 24, 444-448.	1.9	18
14	Inherited DNA-repair gene mutations in African American men with prostate cancer. <i>Oncotarget</i> , 2020, 11, 440-442.	0.8	18
15	Germline <i>BLM</i> mutations and metastatic prostate cancer. <i>Prostate</i> , 2020, 80, 235-237.	1.2	15
16	Laboratory-Based Biomarkers and Liver Metastases in Metastatic Castration-Resistant Prostate Cancer. <i>Oncologist</i> , 2018, 23, 791-797.	1.9	13
17	Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer. <i>BMC Cancer</i> , 2019, 19, 524.	1.1	12
18	Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline <i>ATM</i> versus <i>BRCA2</i> mutations. <i>Prostate</i> , 2021, 81, 1382-1389.	1.2	10

#	ARTICLE	IF	CITATIONS
19	Evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer. <i>Oncotarget</i> , 2020, 11, 15-21.	0.8	9
20	TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 148-154.	0.9	7
21	Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients. <i>Prostate</i> , 2021, 81, 427-432.	1.2	7
22	Eradication of BRAF K601E Mutation in Metastatic Castrate-resistant Prostate Cancer Treated With Cabazitaxel and Carboplatin: A Case Report. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e312-e314.	0.9	6
23	Relationship between serum markers and volume of liver metastases in castration-resistant prostate cancer. <i>Cancer Treatment and Research Communications</i> , 2019, 20, 100151.	0.7	5
24	Prostate-specific Antigen Response and Eradication of Androgen Receptor Amplification with High-dose Testosterone in Prostate Cancer. <i>European Urology</i> , 2017, 71, 997-998.	0.9	4
25	Estrogen-Mediated Activation of H875Y Androgen Receptor Mutation in a Prostate Cancer Patient. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e111-e113.	0.9	4
26	The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases. <i>Prostate</i> , 2022, 82, 1202-1209.	1.2	4
27	Long-Term Disease Control Using Taxane/Platinum-Based Chemotherapy in CDK12-Mutated Advanced Prostate Cancer. <i>Oncologist</i> , 2020, 25, e1421-e1422.	1.9	3
28	Characterizations of Clinical and Therapeutic Histories for Men With Prostate Cancer-Specific Mortality. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 139-148.	0.9	2
29	Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. <i>Cancer Treatment and Research Communications</i> , 2020, 24, 100193.	0.7	2
30	High-Dose Testosterone and Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 476-479.	0.9	1
31	Letter to the Editor: "Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients". <i>Prostate</i> , 2021, 81, 1262-1263.	1.2	0
32	EPID-03. SINGLE INSTITUTIONAL CLINICAL AND GENETIC ANALYSIS OF METASTATIC PROSTATE CANCER WITH AND WITHOUT BRAIN METASTASES. <i>Neuro-Oncology</i> , 2020, 22, ii78-ii79.	0.6	0
33	Cancer-derived C-terminus-extended p53 mutation confers dominant-negative effect on its wild-type counterpart. <i>Journal of Molecular Cell Biology</i> , 2022, 14, .	1.5	0